Fed Circ refuses to stay Novartis feud with MSN over Entresto

Litigation concerns Novartis’ blockbuster $6bn heart failure drug, which has already expired | Indian generic company hoped to stay proceedings to prepare appeal against unfavourable decision.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novartis and MSN feud intensifies after Fed Circ denies rehearing

27 March 2025 Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent should be delisted from the Orange Book | Novartis urges injunction to block generic version of heart treatment before regulatory gap closes.

Big Pharma

Novartis wins appeal in MSN clash over heart drug generic

14 January 2025 Federal circuit reverses district court’s ruling to revive combination patent | Novartis says patent has paediatric exclusivity expiring in July 2025.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Fed Circ refuses to stay Novartis feud with MSN over Entresto

More on this story

Editor's picks

Editor's picks

More features